- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04008004
A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)
A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EDP 514 in Healthy Subjects (Part 1), and Antiviral Activity in Nucleos(t)Ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients With Chronic Hepatitis B Virus Infection (Part 2)
Part 1 is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-514 in healthy adult subjects.
Part 2 is randomized, double -blind, placebo-controlled study including subjects with Hepatitis B Virus. It will assess the safety, tolerability, pharmacokinetics and antiviral activity of 28 Days of orally administered doses of EDP-514 in nucleos(t)ide reverse transcriptase inhibitor (NUC)-Suppressed Patients with Chronic Hepatitis B Virus Infection
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Part 1 consists of two phases planned in healthy subjects:
The first phase assesses single ascending doses for EDP-514 (active drug or placebo) in healthy subjects. A "fasted" and "fed" two-part cohort will also assess food effect.
The second phase assesses multiple ascending doses (active drug or placebo) for 14 days in healthy subjects.
Each cohort within each phase will enroll a total of 8 subjects who will be randomized to receive EDP-514 or placebo. The cohort assessing food effect will enroll 10 subjects randomized to receive EDP-514 or placebo.
Part 2 assesses multiple ascending doses EDP-514 (active drug or placebo) for 28 days in nucleos(t)ide reverse transcriptase inhibitor (NUC)-Suppressed Patients with Chronic Hepatitis B Virus Infection.
Each cohort in Part 2 will enroll a total of 8 subjects who will be randomized to receive EDP-514 or placebo.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
California
-
Coronado, California, Förenta staterna, 92118
- Southern California GI and Liver Centers
-
Los Angeles, California, Förenta staterna, 90095
- University of California Los Angeles
-
San Diego, California, Förenta staterna, 92105
- Tuan Nguyen Md Gastroenterology & Hepatology (Tuan Nguyen, M.D., Inc.)
-
San Francisco, California, Förenta staterna, 94115
- Quest Clinical Research
-
-
Florida
-
Miami, Florida, Förenta staterna, 33136
- University of Miami Miller School of Medicine
-
-
Kansas
-
Lenexa, Kansas, Förenta staterna, 66219
- Pharmaceutical Research Associates, Inc.
-
-
Maryland
-
Catonsville, Maryland, Förenta staterna, 21228
- Digestive Disease Associates - Catonsville
-
-
New York
-
New York, New York, Förenta staterna, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- American Research Corporation
-
San Antonio, Texas, Förenta staterna, 78215
- The Texas Liver Institute
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98104
- Swedish Organ Transplant and Liver Center
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 4Z6
- University of Calgary
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6Z 2K5
- Gastroenterology Institute of Research Institute
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 2C4
- Toronto General Hospital
-
-
Quebec
-
Montréal, Quebec, Kanada, H2X 0A9
- Centre Hospitalier de l'Universite de Montreal
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Part 1 (HV Population):
Inclusion Criteria:
- An informed consent document signed and dated by the subject.
- Healthy male and female subjects of any ethnic origin between the ages of 18 and 65 years, inclusive.
Exclusion Criteria:
- Clinically relevant evidence or history of illness or disease.
- Pregnant or nursing females.
- History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
- A positive urine drug screen at screening or Day -1.
- Current tobacco smokers or use of tobacco within 3 months prior to screening.
- Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).
- History of regular alcohol consumption.
- Receipt of any vaccine, an investigational agent or biological product within 28 days or 5 times the t½, whichever one is longer, prior to first dose. This includes agents administered during clinical trial participation.
Part 2 (HBV Population):
Inclusion Criteria:
- An informed consent document signed and dated by the subject.
- Healthy male and female subjects of any ethnic origin between the ages of 18 and 70 years, inclusive
HBV DNA levels:
- A Screening HBV DNA level in serum/plasma that is <LLOQ and
- No HBV DNA serum/plasma test values ≥LLOQ over the previous 12 months (using an approved test)
- CHB subjects must have been on their prescribed HBV NUC treatment with no change in regimen for 12 months prior to Screening
Exclusion Criteria:
- A documented prior diagnosis of cirrhosis
- Pregnant or nursing females
- Coinfection with human immunodeficiency virus (HIV), HCV, HDV, HAV, or HEV
- Chronic liver disease of a non-HBV etiology; coexisting liver or biliary diseases
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: EDP-514 HV SAD Cohorts
EDP-514 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 orally, once daily in one single administration
|
Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).
|
Experimentell: EDP-514 HV MAD Cohorts
EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 14 days
|
Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).
|
Placebo-jämförare: EDP-514 HV SAD Placebo Cohort
Matching placebo, orally, once daily in one single administration
|
Placebo för att matcha EDP-514
|
Placebo-jämförare: EDP-514 HV MAD Placebo Cohort
Matching placebo, orally, once daily for 14 days
|
Placebo för att matcha EDP-514
|
Experimentell: EDP-514 HBV MAD Cohorts
EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 28 days
|
Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).
|
Placebo-jämförare: EDP-514 HBV MAD Placebo Cohort
Matching placebo, orally, once daily for 28 days
|
Placebo för att matcha EDP-514
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Säkerhet mätt med biverkningar
Tidsram: Upp till 8 dagar i HV SAD-kohorter
|
Upp till 8 dagar i HV SAD-kohorter
|
Säkerhet mätt med biverkningar
Tidsram: Upp till 21 dagar i HV MAD-kohorter
|
Upp till 21 dagar i HV MAD-kohorter
|
Safety measured by adverse events
Tidsram: Up to 56 Days in HBV MAD Cohorts
|
Up to 56 Days in HBV MAD Cohorts
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Cmax of EDP-514
Tidsram: Up to 6 Days in HV SAD Cohorts
|
Up to 6 Days in HV SAD Cohorts
|
AUC of EDP-514
Tidsram: Up to 6 Days in HV SAD Cohorts
|
Up to 6 Days in HV SAD Cohorts
|
Cmax of EDP-514
Tidsram: Up to 18 Days in HV MAD Cohorts
|
Up to 18 Days in HV MAD Cohorts
|
AUC of EDP-514
Tidsram: Up to 18 Days in HV MAD Cohorts
|
Up to 18 Days in HV MAD Cohorts
|
Cmax för EDP-514
Tidsram: Upp till 28 dagar i HBV MAD-kohorter
|
Upp till 28 dagar i HBV MAD-kohorter
|
AUC för EDP-514
Tidsram: Upp till 28 dagar i HBV MAD-kohorter
|
Upp till 28 dagar i HBV MAD-kohorter
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Patologiska processer
- Blodburna infektioner
- Sjukdomsegenskaper
- Leversjukdomar
- Hepatit, Viral, Human
- Hepadnaviridae-infektioner
- DNA-virusinfektioner
- Hepatit, kronisk
- Infektioner
- Smittsamma sjukdomar
- Hepatit B
- Hepatit
- Virussjukdomar
- Hepatit B, kronisk
- Herpesviridae-infektioner
Andra studie-ID-nummer
- EDP 514-001
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Kronisk HBV-infektion
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Duke-NUS Medical School (Singapore)Har inte rekryterat ännuHBV | HBV/HDVItalien
-
Centre de Recherches et d'Etude sur la Pathologie...Avslutad
-
Aucta Pharmaceuticals, IncAvslutad
-
The First Hospital of Jilin UniversityOkänd
-
Institute of Liver and Biliary Sciences, IndiaIndragen
-
Yi-Hua ZhouThe First People's Hospital of Kunshan; Taixing People's Hospital; Fourth... och andra samarbetspartnersAvslutad
-
RenJi HospitalHar inte rekryterat ännuHBV | Levertransplantationsstörning
-
West China HospitalRekryteringNjurtransplantation | HBVKina
-
Clínica de Oftalmología de Cali S.AAvslutadMeibomisk körteldysfunktion | Eyes Dry ChronicColombia
-
Fudan UniversityAktiv, inte rekryterandeHBV | EFTER LEVERTRANSPLANTERINGKina
Kliniska prövningar på EDP-514
-
Enanta Pharmaceuticals, IncPharmaceutical Research AssociatesAvslutadKronisk HBV-infektionHong Kong, Taiwan
-
Enanta Pharmaceuticals, IncAvslutadKronisk hepatit B-virusinfektionNya Zeeland
-
Caliway Biopharmaceuticals Co., Ltd.AvslutadCelluliterFörenta staterna
-
Caliway Biopharmaceuticals Co., Ltd.Avslutad
-
Caliway Biopharmaceuticals Co., Ltd.Avslutad
-
Caliway Biopharmaceuticals Co., Ltd.Avslutad
-
Caliway Biopharmaceuticals Co., Ltd.AvslutadDercums sjukdomFörenta staterna
-
Caliway Biopharmaceuticals Co., Ltd.Aktiv, inte rekryterandeCelluliterFörenta staterna
-
Zhujiang HospitalAvslutadAkut exacerbation av kronisk obstruktiv lungsjukdomKina
-
Caliway Biopharmaceuticals Co., Ltd.AvslutadSubkutant fettFörenta staterna